Olon Group has been selected as “Champion” in five categories of 2023 CDMO Leadership Awards and won recognition across categories including capabilities, compatibility, expertise, quality, and reliability.
Olon has been given recognition as a CDMO Leadership Award Champion for scoring as a top performer in comparison to the weighted average of other CDMOs included in ISR’s annual Contract Manufacturing Quality Benchmarking survey.
“For over a decade, these awards have proven most meaningful for biopharma organisations striving to obtain optimal outcomes from their outsourcing activities. Our research arm, Industry Standard Research (ISR), which only surveys drug sponsors who have worked recently with specific CDMOs, ensures the validity of these results. Our winners will be your champions of outsourcing,” Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma.
Winning these awards reinforces our commitment to quality excellence, reliability and flexibility that we offer to our pharma partners
“We are proud to be recognised as Champion in five CDMO leadership categories, out of six. This recognition reflects the dedication of our team to support our customers,” said Paolo Tubertini, Olon’s CEO. “Winning these awards reinforces our commitment to quality excellence, reliability and flexibility that we offer to our pharma partners”.
Olon Group is a global leader in the development and production of active pharmaceutical ingredients (APIs) for CDMO and generic markets, integrating chemical synthesis and biological processes while always embracing the highest international safety, quality, and environmental standards.
The company has a global network of 11 manufacturing sites and 7 R&D centres across the globe. Thanks to its 2,300 employees, including 300 highly experienced and qualified R&D experts, the company represents a highly innovative and reliable partner.
